CRISPR Therapeutics AG Annual Nonoperating Income (Expense) in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
CRISPR Therapeutics AG quarterly/annual Nonoperating Income (Expense) history and growth rate from 2014 to 2023.
  • CRISPR Therapeutics AG Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $26.1M, a 42% increase year-over-year.
  • CRISPR Therapeutics AG Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $91.5M, a 83.4% increase year-over-year.
  • CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2023 was $71.8M, a 217% increase from 2022.
  • CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2022 was $22.7M, a 277% increase from 2021.
  • CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2021 was $6M, a 5.89% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $71.8M +$49.2M +217% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 $22.7M +$16.7M +277% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 $6M -$376K -5.89% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 $6.38M -$14.2M -69% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $20.6M +$26.1M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$5.49M -$3.53M -180% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$1.96M -$47.4M -104% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 $45.4M +$45.5M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
2015 -$92K +$144K +61% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$236K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.